Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin mesylate was approved by the U.S. Food and Drug Administration on November 15 2010 to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease including both anthracycline- and taxane-based chemotherapies.
This page contains content from the copyrighted Wikipedia article "Eribulin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
